Document Detail

The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test.
MedLine Citation:
PMID:  15702856     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The intake of proton pump inhibitors may interfere with the reliability of the urea breath test. AIM: Prospective study to assess the accuracy of the urea breath test during the first days of therapy with proton pump inhibitors. PATIENTS: Thirty patients who needed to start proton pump inhibitors therapy and 53 volunteers. METHODS: A 13C-urea breath test was performed respectively before starting proton pump inhibitors therapy and every morning before its intake up until 10 days. The test was considered positive for values of 13CO2 > or = 3.0% delta over baseline. The coefficient of reproducibility for 95% interval of confidence of the urea breath test was calculated in both groups. RESULTS: Of the 30 patients receiving proton pump inhibitors, 47% were positive for Helicobacter pylori. Among these, 43% developed false negative breath tests in the first 10 days. False positive results occurred in 37.5% of H. pylori-negative subjects in the first 10 days. The coefficient of reproducibility of the urea breath test was significantly higher in the group treated with proton pump inhibitors (11.0 versus 1.8 for the control group, p < 0.0001). CONCLUSION: The intake of proton pump inhibitors impairs the accuracy of the 13C-urea breath test. False negative and false positive 13C-urea breath tests are common, occur as soon as after 1 day and increase with prolonged duration of treatment. The coefficient of reproducibility of the test in patients receiving proton pump inhibitors is not acceptable for clinical purpose and the test should not be performed once the medication has been started.
F Mana; W Van Laer; W Van Laere; A Bossuyt; D Urbain
Related Documents :
3888766 - Cholecystokinetic cholecystography.
21848076 - Comparison between invasive and noninvasive tests in diagnosis of helicobacter pylori i...
16725376 - Elderly patients with unexplained syncope: what should be considered a positive tilt te...
16635906 - Evaluation of the necessity of induction for lactose-[15n, 15n]-ureide to study the col...
17674316 - Selective testing criteria for gonorrhea among young women screened for chlamydial infe...
3724836 - Study of a madurella grisea strain isolated from a foot mycetoma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver     Volume:  37     ISSN:  1590-8658     ISO Abbreviation:  Dig Liver Dis     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2005-02-10     Completed Date:  2005-04-08     Revised Date:  2009-10-02    
Medline Journal Info:
Nlm Unique ID:  100958385     Medline TA:  Dig Liver Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  28-32     Citation Subset:  IM    
Department of Gastroenterology, Free University of Brussels, Academisch Ziekenhuis, Laarbeeklaan 101, B-1090 Brussels, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breath Tests*
Carbon Isotopes / diagnostic use
Enzyme Inhibitors / pharmacology*
Gastritis / diagnosis*,  drug therapy,  microbiology
Helicobacter Infections / drug therapy*
Helicobacter pylori*
Omeprazole / analogs & derivatives*,  pharmacology,  therapeutic use
Prospective Studies
Proton Pumps / antagonists & inhibitors*
Sensitivity and Specificity
Urea / diagnostic use
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Carbon Isotopes; 0/Enzyme Inhibitors; 0/Proton Pumps; 103577-45-3/lansoprazole; 57-13-6/Urea; 73590-58-6/Omeprazole
Erratum In:
Dig Liver Dis. 2009 Aug;41(8):613
Note: Van Laere, W [corrected to Van Laer, W]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cornstarch thickened formula reduces oesophageal acid exposure time in infants.
Next Document:  Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinid...